Hephaistos.bio Raises €161K for Sustainable Enzyme Design

Swiss deeptech firm hephaistos.bio has successfully raised €161,000 (CHF 150,000) in a seed funding round led by Venture Kick. This capital injection is earmarked to accelerate the development of novel enzyme solutions, crucial for advancing sustainable practices within the chemical and pharmaceutical manufacturing sectors.

The chemical industry, a cornerstone of modern economies, faces significant pressure to decarbonize and enhance supply chain resilience. Traditional synthesis methods are often energy-intensive and generate substantial waste. Enzymes, as biological catalysts, present a compelling alternative, offering pathways for more efficient, cost-effective, and environmentally benign production processes. However, a critical gap exists for tailored biocatalysts needed for many complex industrial reactions, particularly in high-value pharmaceutical synthesis.

hephaistos.bio is strategically positioned to bridge this gap. The company leverages a sophisticated, integrated platform that combines computational biology, advanced chemistry, machine learning, and structural biology. This multidisciplinary approach enables the precise design of custom protein catalysts, engineered to meet the specific demands of industrial chemical transformations. Their proprietary technology aims to unlock reactions previously deemed impractical or inefficient with existing enzymatic tools.

The startup's innovative end-to-end enzyme design system is designed to simplify complex manufacturing workflows. By providing bespoke biocatalysts, hephaistos.bio empowers manufacturers to not only reduce their environmental footprint but also to bolster operational efficiency and cost competitiveness. This is particularly relevant as industries look to reshore production and build more robust domestic supply chains.

Founded by a team with deep expertise across relevant disciplines, including Lukas Radtke (CEO), Lucas Merlicek (CTO), Jannik Neumann (Head of Operations), Moritz Ullhofen (Head of Lab), and Ilya Schneider (Head of Business Development), hephaistos.bio is already demonstrating commercial viability. The company has initiated an industrial pilot project with the Swiss contract research organization SpiroChem, validating the practical application and market demand for its custom enzyme solutions.

With this new funding, hephaistos.bio intends to significantly enhance its enzyme design capabilities. Key initiatives include expanding laboratory automation to speed up development cycles and making its first strategic hires. These advancements will bolster the company's capacity to support pharmaceutical and fine chemical companies seeking greener and more economical alternatives to conventional chemical synthesis, potentially reshaping European manufacturing processes.